During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Organon OGN shares soared 8.5% in the last trading session to close at $12.64. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

This information is based on a press release statement from Biogen. In other recent news, Organon has acquired the U.S. regulatory and commercial rights for TOFIDENCE™, a biosimilar to ACTEMRA®, from ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Credit: testing/Shutterstock. Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is ...

JERSEY CITY, N.J. - Organon (NYSE: OGN), a global healthcare company, has acquired the U.S. regulatory and commercial rights for TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen Inc. (NASDAQ: BIIB), ...

NEW YORK — Zohran Mamdani, the most left-leaning candidate in this summer’s mayoral election, rolled out a public safety plan Tuesday that hinges on launching a new city agency tasked ...

Under the terms of the agreement, Organon has acquired the regulatory and commercial rights to TOFIDENCE in the U.S., available in three vial sizes, 80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL ...